Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group
Mandate

Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group

January 15, 2021 M&A

Vinge is advising Capillar Equity Investment I in connection with the sale of shares in Nordic Surface Group (“NSG”) to a funds managed by Litorina and Bragnum, respectivley. NSG’s management will remain as significant co-owners in the group consisting of six local market leaders formed by Capillar Equity in 2020.

The company offers painting and other surface services such as flooring, tiling and facade finishing in Sweden and combined reported a revenue of SEK 1bn with 800 FTEs in 2020.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

The Vinge team advising on the transaction includes partner Christina Kokko with the associates Michaela Cronemyr, Johanna Wiberg and Ellinor Wargenbrant.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025